Background
California (CA) State Bill 159 (SB159), enacted in October 2019, aimed to expand PrEP access and reduce HIV incidence by broadening authority for pharmacists to prescribe PrEP without physician approval and prohibiting insurance preauthorization requirements. This study examined SB159’s impact on pharmacist PrEP prescribing, changes in number of PrEP prescriptions filled, and the relation between PrEP use and HIV incidence across counties.
Methods
We analyzed PrEP prescriptions using the claims-based IQVIA Longitudinal Access and Adjudication Dataset (2015–2024) and HIV incidence data from the CA Office of AIDS (2018–2022) at the state and county-level. Interrupted time series assessed changes in both mean levels and slopes before and after implementation of SB159 for 1) frequency of pharmacists prescribing PrEP post-SB159 (adjusted for patient age and sex) 2) the number of PrEP prescriptions filled, and 3) the association between overall PrEP use and HIV incidence 12 months later (adjusted for sex).
Results
Pharmacist prescribing in CA increased following SB159 from a baseline of median 11.5 pharmacists prescribed PrEP per quarter (IQR 9–13) to 29 (IQR 23.5–30) (Figure). By 2024, the number of pharmacists prescribing PrEP per quarter in CA was estimated to be 14 higher than expected based on pre-SB159 trends (interaction OR=2.16, 95%CI 1.49–3.15, p<.001). There was also a non-significant trend in which each pharmacist prescribed ~16 more PrEP prescriptions across the post-SB159 period (p=.057). However, pharmacist prescribing made up <1% of total PrEP prescriptions.
At the county level, each 1-SD increase in receipt of PrEP prescriptions predicted a 7% reduction in HIV cases 12 months later (OR=0.93, 95%CI 0.92–0.94, p<.001). However, overall PrEP use plateaued during this time period (OR=0.98, 95%CI 0.98–0.98, p<.001) which spanned the COVID-19 period. HIV cases accelerated during the study timeframe, with each month linked to a 36% higher odds of cases compared to pre-November 2019 trends (interaction OR=1.36, 95%CI 1.20–1.55, p<.001).
Conclusions
Legislative changes allowing pharmacist prescribing of PrEP significantly increased the number of pharmacists prescribers despite a low overall prevalence. Higher county-level uptake predicted lower HIV incidence. However, statewide prescriptions plateaued during COVID-19, coinciding with rising HIV cases. Results reflect the impact of state legislation as well as broader system challenges, underscoring the ongoing need to expand PrEP use.
Table or Figure
